Diamyd Medical Patents

Patent portfolio assigned to Diamyd Medical (verified via public assignee records). Estimated patent count: 6. Swedish clinical-stage diabetes company (GAD65 antigen-specific immunotherapy Diamyd, Phase 3 DIAGNODE-3; also Remygen). Multiple Google Patents list 'Diamyd Medical AB' as assignee (GAD/GABA/antigen formulations). Provention Bio (teplizumab) is the field's reference competitor per Diamyd's own CEO statement; Scandinavian Biopharma from Growjo. Cytiva is a manufacturing supplier/partner. Patent count is an estimate from visible assignee results.